H
Horst Lindhofer
Researcher at University of Hamburg
Publications - 106
Citations - 3670
Horst Lindhofer is an academic researcher from University of Hamburg. The author has contributed to research in topics: Catumaxomab & Trifunctional antibody. The author has an hindex of 28, co-authored 103 publications receiving 3404 citations.
Papers
More filters
Patent
Time-staggered utilization of tumor cells in combination with intact antibodies for immunization
Horst Lindhofer,Peter Ruf +1 more
TL;DR: In this article, the time-staggered utilization of tumor cells in combination with intact, preferably heterologous antibodies for the immunization of humans and animals was proposed, which relates to the use of tumor stem cells for cancer immunization.
Journal ArticleDOI
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
Maren Knödler,Justus Körfer,Volker Kunzmann,Jörg Trojan,Severin Daum,Michael Schenk,Frank Kullmann,Sebastian Schroll,Dirk Behringer,Michael Stahl,Salah-Eddin Al-Batran,Ulrich Hacker,Stefan Ibach,Horst Lindhofer,Florian Lordick +14 more
TL;DR: Addition of catumaxomab to systemic chemotherapy was feasible and tolerable in advanced GC and results are promising for future investigations integrating intraperitoneal immunotherapy into a multimodal treatment strategy.
Journal ArticleDOI
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
N. Haense,Akin Atmaca,Claudia Pauligk,Kristina Steinmetz,Frederik Marmé,G.M. Haag,Michael A. Rieger,Oliver G. Ottmann,P. Ruf,Horst Lindhofer,Salah-Eddin Al-Batran +10 more
TL;DR: Single doses up to 300 μg were well tolerated and could be safely administered in an escalating dose scheme and immunological responses and clinical activity warrant further evaluation in patients with Her2 over expressing tumors.
Journal ArticleDOI
Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.
Friedhelm R. Schuster,Michael Stanglmaier,Wilhelm Woessmann,Beate Winkler,Meinolf Siepermann,Roland Meisel,Paul G. Schlegel,Jürgen Hess,Horst Lindhofer,Arndt Borkhardt,Raymund Buhmann +10 more
TL;DR: Despite the dismal clinical prognosis of childrenRefractory to standard therapy, immunotherapy with Lymphomun resulted in a favourable clinical outcome in this cohort of refractory paediatric patients.
Patent
Destruction of contaminating tumor cells in stem cell transplants using bispecific antibodies
TL;DR: In this article, a procedure for the destruction of contaminating tumor cells in stem cell transplants ex vivo using intact bispecific antibodies is described, and the procedure is described in detail.